1. Duocarmycin-based antibody–drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress
- Author
-
Ming-Hai Wang, Hui Zhao, Xiang-Min Tong, Hangping Yao, and Rachel Hudson
- Subjects
Pharmacology ,Drug ,Antibody-drug conjugate ,Immunoconjugates ,business.industry ,media_common.quotation_subject ,Drug Evaluation, Preclinical ,Cancer therapy ,Antineoplastic Agents ,Computational biology ,body regions ,Duocarmycins ,chemistry.chemical_compound ,Drug Development ,chemistry ,Neoplasms ,Drug Discovery ,Animals ,Humans ,Medicine ,business ,Duocarmycin ,media_common - Abstract
Duocarmycins are a class of DNA minor-groove-binding alkylating molecules. For the past decade, various duocarmycin analogues have been used as payloads in the development of antibody-drug conjugates (ADCs). Currently, more than 15 duocarmycin-based ADCs have been studied preclinically, and some of them such as SYD985 have been granted Fast-Track Designation status. Nevertheless, progress in duocarmycin-based ADCs also faces challenges, with setbacks including the termination of BMS-936561/MDX-1203. In this review, we discuss issues associated with the efficacy, pharmacokinetic profile, and toxicological activity of these biotherapeutics. Furthermore, we summarize the latest advances in duocarmycin-based ADCs that have different target specificities and linker chemistries. Evidence from preclinical and clinical studies has indicated that duocarmycin-based ADCs are promising biotherapeutics for oncological application in the future.
- Published
- 2021